<li>amitriptyline<p>simvastatin will increase the level or effect of amitriptyline by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>atorvastatin<p>simvastatin will increase the level or effect of atorvastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>azithromycin<p>simvastatin will increase the level or effect of azithromycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>bazedoxifene/conjugated estrogens<p>simvastatin will increase the level or effect of bazedoxifene/conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>budesonide<p>simvastatin will increase the level or effect of budesonide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>carbamazepine<p>carbamazepine will increase the level or effect of simvastatin by  Other (see comment). Use Caution/Monitor. OATP1B1 inhibitors may increase risk of myopathy</p></li><li>caspofungin<p>caspofungin will increase the level or effect of simvastatin by  Other (see comment). Use Caution/Monitor. OATP1B1 inhibitors may increase risk of myopathy</p></li><li>ceritinib<p>simvastatin increases levels of ceritinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>cholestyramine<p>cholestyramine decreases levels of simvastatin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cholic acid<p>simvastatin increases toxicity of cholic acid by decreasing elimination. Modify Therapy/Monitor Closely. Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP). May exacerbate accumulation of conjugated bile salts in the liver and result in clinical symptoms. If concomitant use is necessary, monitor serum transaminases and bilirubin.</p></li><li>clobetasone<p>simvastatin will increase the level or effect of clobetasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>clotrimazole<p>clotrimazole will increase the level or effect of simvastatin by  Other (see comment). Use Caution/Monitor. OATP1B1 inhibitors may increase risk of myopathy</p></li><li>colchicine<p>simvastatin will increase the level or effect of colchicine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>conjugated estrogens<p>simvastatin will increase the level or effect of conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>conjugated estrogens, vaginal<p>simvastatin will increase the level or effect of conjugated estrogens, vaginal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>cortisone<p>simvastatin will increase the level or effect of cortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>crizotinib<p>crizotinib increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.</p></li><li>crofelemer<p>crofelemer increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of simvastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor for HMG-CoA reductase inhibitor associated adverse events (eg, myopathy).<span><br><br></span>daclatasvir will increase the level or effect of simvastatin by  Other (see comment). Use Caution/Monitor. Daclatasvir inhibits OATP1B1, OATP1B3, and BCRP. Caution if coadministered with drugs that are substrates of these transporters. Monitor for HMG-CoA reductase inhibitor associated adverse events (eg, myopathy).</p></li><li>daclizumab<p>daclizumab, simvastatin. Other (see comment). Use Caution/Monitor. 
Comment: Caution should be used if hepatotoxic drugs are coadministered, including nonprescription drugs. Both drugs reported to cause autoimmune hepatitis.</p></li><li>daptomycin<p>simvastatin, daptomycin.
Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Coadministration of daptomycin with HMG-CoA reductase inhibitors may increase CPK levels and risk for myopathy; consider temporary suspension of HMG-CoA reductase inhibitors during daptomycin therapy.</p></li><li>deferasirox<p>deferasirox will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>deflazacort<p>simvastatin will increase the level or effect of deflazacort by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dexamethasone<p>simvastatin will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>digoxin<p>simvastatin will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>digoxin increases toxicity of simvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>docetaxel<p>simvastatin will increase the level or effect of docetaxel by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for signs and symptoms of myopathy in patients receiving dronedarone concurrently with simvastatin</p></li><li>efavirenz<p>efavirenz will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>elbasvir/grazoprevir<p>elbasvir/grazoprevir increases levels of simvastatin by unknown mechanism. Modify Therapy/Monitor Closely. If coadministered, use lowest necessary simvastatin dose.</p></li><li>eliglustat<p>eliglustat increases levels of simvastatin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.</p></li><li>eluxadoline<p>eluxadoline increases levels of simvastatin by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered BCRP substrates. .</p></li><li>estradiol<p>simvastatin will increase the level or effect of estradiol by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>estropipate<p>simvastatin will increase the level or effect of estropipate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>fludrocortisone<p>simvastatin will increase the level or effect of fludrocortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>glyburide<p>glyburide increases toxicity of simvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>hydrocortisone<p>simvastatin will increase the level or effect of hydrocortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>iloperidone<p>iloperidone increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>irinotecan liposomal<p>simvastatin will increase the level or effect of irinotecan liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>itraconazole<p>simvastatin will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ivermectin<p>simvastatin will increase the level or effect of ivermectin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lanthanum carbonate<p>lanthanum carbonate decreases levels of simvastatin by cation binding in GI tract. Use Caution/Monitor. Administer statin at least 2 hr before or 2 hr after lanthanum. Monitor serum concentrations.</p></li><li>loperamide<p>simvastatin will increase the level or effect of loperamide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lovastatin<p>simvastatin will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>mestranol<p>simvastatin will increase the level or effect of mestranol by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>methylprednisolone<p>simvastatin will increase the level or effect of methylprednisolone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>metyrapone<p>metyrapone increases toxicity of simvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>mipomersen<p>mipomersen, simvastatin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>mitotane<p>mitotane decreases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>netilmicin<p>simvastatin will increase the level or effect of netilmicin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of simvastatin by  Other (see comment). Use Caution/Monitor. Paritaprevir inhibits OATP1B1, OATP1B3, and BCRP. Ritonavir inhibits BCRP. Caution if coadministered with drugs that are substrates of these transporters.<span><br><br></span>ombitasvir/paritaprevir/ritonavir will increase the level or effect of simvastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Paritaprevir and ritonavir inhibit P-gp. Caution if coadministered with P-gp substrates.</p></li><li>paclitaxel<p>simvastatin will increase the level or effect of paclitaxel by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>paclitaxel increases toxicity of simvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>paclitaxel protein bound<p>simvastatin will increase the level or effect of paclitaxel protein bound by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>paliperidone<p>simvastatin will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>pazopanib<p>simvastatin increases toxicity of pazopanib by Other (see comment). Use Caution/Monitor. 
Comment: Increased risk of elevated LFTs with pazopanib when coadministered with simvastatin.<span><br><br></span>pazopanib will increase the level or effect of simvastatin by  Other (see comment). Use Caution/Monitor. OATP1B1 inhibitors may increase risk of myopathy</p></li><li>pioglitazone<p>pioglitazone increases toxicity of simvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>ponatinib<p>ponatinib increases levels of simvastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>ponatinib increases levels of simvastatin by Other (see comment). Use Caution/Monitor.</p></li><li>posaconazole<p>simvastatin will increase the level or effect of posaconazole by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>prednisolone<p>simvastatin will increase the level or effect of prednisolone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>prednisone<p>simvastatin will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>repaglinide<p>repaglinide increases toxicity of simvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>rifampin<p>rifampin will increase the level or effect of simvastatin by  Other (see comment). Use Caution/Monitor. OATP1B1 inhibitors may increase risk of myopathy</p></li><li>risperidone<p>simvastatin will increase the level or effect of risperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rosiglitazone<p>rosiglitazone increases toxicity of simvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>sacubitril/valsartan<p>simvastatin will increase the level or effect of sacubitril/valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>silodosin<p>simvastatin will increase the level or effect of silodosin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>simeprevir<p>simeprevir increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Simeprevir inhibits OATP1B1 and/or CYP3A4; when coadministered with simeprevir, titrate simvastatin to lowest necessary dose and monitor.</p></li><li>sirolimus<p>simvastatin will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>sofosbuvir/velpatasvir<p>sofosbuvir/velpatasvir will increase the level or effect of simvastatin by  Other (see comment). Modify Therapy/Monitor Closely. Velpatasvir is an inhibitor of the drug transporter BCRP. Coadministration may increase systemic exposure of drugs that are BCRP substrates. Coadministration may significantly increase simvastatin serum concentration, which is associated with increased risk of myopathy, including rhabdomyolysis.</p></li><li>tacrolimus<p>simvastatin will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>tacrolimus increases toxicity of simvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>ticagrelor<p>ticagrelor increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid simvastatin doses greater than 40 mg.</p></li><li>tolvaptan<p>simvastatin will increase the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>triamcinolone<p>simvastatin will increase the level or effect of triamcinolone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>valsartan<p>simvastatin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>vinblastine<p>simvastatin will increase the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vincristine<p>simvastatin will increase the level or effect of vincristine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vincristine liposomal<p>simvastatin will increase the level or effect of vincristine liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vismodegib<p>simvastatin will increase the level or effect of vismodegib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Vismodegib is a substrate of efflux transporter P-glycoprotein (P-gp); coadministration with P-gp inhibitors increase vismodegib systemic exposure</p></li><li>warfarin<p>simvastatin, warfarin.
Either increases effects of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Competition by each drug for CYP3A4-mediated metabolism may result in increased INR and increased risk of rhabdomyolysis.</p></li>